Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Boehringer Ingelheim
Deloitte
Queensland Health
Cipla
Federal Trade Commission
Colorcon
Merck

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204223

« Back to Dashboard

NDA 204223 describes MORPHINE SULFATE, which is a drug marketed by Actavis Elizabeth, Impax Labs Inc, Par Pharm Inc, Teva Pharms Usa, Upsher-smith Labs, Eurohlth Intl Sarl, Hospira, Hospira Inc, Icu Medical Inc, Meridian Medcl Techn, Specgx Llc, Watson Labs, Fresenius Kabi Usa, Hi-tech Pharmacal, Lannett Holdings Inc, Nostrum Labs Inc, Paddock Llc, Pharm Assoc, Rhodes Pharms, Tris Pharma Inc, Vintage Pharms Llc, Vistapharm, West-ward Pharms Int, Dava Pharms Inc, Epic Pharma Llc, Mayne Pharma Inc, Mylan Pharms Inc, Nesher Pharms, Novel Labs Inc, Sun Pharm Inds Ltd, and Sun Pharm Industries, and is included in fifty-three NDAs. It is available from forty-eight suppliers. There are three patents protecting this drug. Additional details are available on the MORPHINE SULFATE profile page.

The generic ingredient in MORPHINE SULFATE is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 204223
Tradename:MORPHINE SULFATE
Applicant:Fresenius Kabi Usa
Ingredient:morphine sulfate
Patents:3
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 204223
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 204223
Suppliers and Packaging for NDA: 204223
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223 NDA Fresenius Kabi USA, LLC 63323-451 N 63323-451-01
MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223 NDA Fresenius Kabi USA, LLC 63323-452 N 63323-452-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULAR, INTRAVENOUSStrength2MG/ML (2MG/ML)
Approval Date:Oct 30, 2013TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 12, 2034Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Mar 12, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
Patent:➤ Sign UpPatent Expiration:Mar 12, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF PAIN

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Baxter
Citi
Queensland Health
Moodys
Cantor Fitzgerald
Fish and Richardson
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.